Effectiveness, safety, and endothelial function effects of atorvastatin lipid-lowering therapy in coronary heart disease patients undergoing percutaneous coronary intervention

Effectiveness, safety, and endothelial function effects of atorvastatin lipid-lowering therapy in coronary heart disease patients undergoing percutaneous coronary intervention

Aim. To study lipid-lowering and pleiotropic atorvastatin effects on lipid metabolism, endothelial function, fibrinogen level in coronary heart disease (CHD) patients who underwent myocardial revascularization (percutaneous coronary intervention). Material and methods. The study included 40 CHD pati...

Full description

Bibliographic Details
Main Authors:	M. P. Mal’gina, O. I. Ignatyeva, N. V. Moroshkina, Yu. V. Skorobogatova, A. O. Nedoshivin, O. A. Berkovich
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2007-06-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	percutaneous coronary intervention myocardial revascularization atorvastatin lipid-lowering and pleiotropic effects
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/1247

Similar Items

Recurrent ischemia after percutaneous coronary intervention
by: M. P. Malgina, et al.
Published: (1970-01-01)

STATINS AND PERCUTANEOUS CORONARY INTERVENTION. FOCUS ON THE ATORVASTATIN
by: N. G. Gogolashvili
Published: (2015-09-01)

ATORVASTATIN IN ACUTE AND CHRONIC KINDS OF ISCHEMIC HEART DISEASE
by: V. E. Oleynikov, et al.
Published: (2015-11-01)

Statinotherapy – the paradigm of prevention and treatment of atherosclerotic pathology (focus on atorvastatin)
by: R. G. Oganov, et al.
Published: (2006-12-01)

ANTIATHEROGENIC AND PLEIOTROPIC ACTIVITY OF VARIOUS DOSES OF ATORVASTATIN IN PATIENTS WITH ISCHEMIC STROKE
by: M. G. Bubnova, et al.
Published: (2013-08-01)

Effect of loading dose of atorvastatin therapy prior to percutaneous coronary intervention in patients with acute coronary syndrome: a meta-analysis of six randomized controlled trials
by: Ma M, et al.
Published: (2019-04-01)

ATORVASTATIN LOADING DOSE BEFORE INTRACORONARY INTERVENTION PROVIDES PROTECTIVE EFFECT IN PATIENTS WITH CHRONIC ATHEROSCLEROTIC TOTAL OCCLUSION OF CORONARY ARTERIES
by: A. S. Ragozina, et al.
Published: (2018-12-01)

Efficacy of atorvastatin on renal function in patients with contrast-induced nephropathy after percutaneous coronary intervention
by: Heng Li, et al.
Published: (2024-10-01)

RECENT ADVANCES IN THE APPLICATION OF HIGH DOSES OF ATORVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE
by: M. V. Ezhov
Published: (2016-01-01)

Atorvastatin suppresses lipopolysaccharide-induced inflammation in human coronary artery endothelial cells
by: Zhen Tian, et al.
Published: (2022-04-01)

Impact of high dose versus low dose atorvastatin on contrast induced nephropathy in diabetic patients with acute coronary syndrome undergoing early percutaneous coronary intervention
by: Haitham Galal, et al.
Published: (2015-12-01)

Atorvastatin effectiveness in dyslipidemia correction among coronary heart disease and arterial hypertension patients with high risk of cardiovascular complications
by: E. V. Minakov, et al.
Published: (2007-10-01)

Factors Associated with Increased Length of Stay in Post Primary Percutaneous Coronary Intervention Patients: A Scoping Review
by: Sugiharto F, et al.
Published: (2023-06-01)

Atorvastatin and prevention of contrast induced nephropathy following coronary angiography
by: Peyman Bidram, et al.
Published: (2015-01-01)

Evaluation of percutaneous coronary intervention and stenting of left main coronary artery stenosis in tehran's rajaie and lavasani hospitals from 2010 to 2011
by: Safarali Abdolrahimi, et al.
Published: (2013-01-01)

Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention in Patients with Distal Left Main Coronary Disease
by: Mohammed Abdelwahed Helyl, et al.
Published: (2022-02-01)

Complex Percutaneous Coronary Intervention Outcomes in Older Adults
by: Jonathan M. Hanna, et al.
Published: (2023-10-01)

Dyslipidemia correction with atorvastatin in patients with coronary heart disease and arterial hypertension
by: N. B. Amirov, et al.
Published: (1970-01-01)

PATHOPHYSIOLOGICAL AND CLINICAL ASPECTS OF HIGH-DOSE ATORVASTATIN CARDIOPROTECTION IN PATIENTS WITH ACUTE CORONARY SYNDROME
by: I. D. Astrakhantseva, et al.
Published: (2018-09-01)

Evaluation of the effect of atorvastatin on corneal endothelial cells during the initial 12-month period after acute coronary syndrome
by: Murat Karapapak, et al.
Published: (2024-07-01)

Pleiotropic vasoprotective effects of high-dose atorvastatin therapy in the context of achieving the target low-density lipoprotein cholesterol in patients after myocardial infarction
by: L. I. Salyamova, et al.
Published: (2022-08-01)

Lipid and pleiotropic effects of atorvastatin in patients with acute coronary syndrome
by: A. A. Yalymov, et al.
Published: (1970-01-01)

The effectiveness of atorvastatin in the prevention of stroke
by: O. D. Ostroumova, et al.
Published: (2015-12-01)

A comparative study on the effects of niacin plus atorvastatin with that of fenofibrate plus atorvastatin in dyslipidemia
by: Selim Ahmed, et al.
Published: (2008-04-01)

Risk Factors for Coronary Events After Robotic Hybrid Off-Pump Coronary Revascularization
by: Aleksander Dokollari, et al.
Published: (2025-01-01)

Anti-inflammatory effects of low- and high-dose atorvastatin therapy in patients with coronary heart disease and rheumatoid arthritis
by: V. S. Tutunov, et al.
Published: (2008-10-01)

Short-term effect of percutaneous coronary intervention on ischemic mitral regurgitation
by: Hazem El-Akabawy, et al.
Published: (2018-09-01)

Efficacy of single high-dose statin prior to percutaneous coronary intervention in acute coronary syndrome: a systematic review and meta-analysis
by: Bryan Gervais de Liyis, et al.
Published: (2024-04-01)

EFFECTS OF ATORVASTATIN ON ENDOTHELIAL DYSFUNCTION IN TYPE 2 DIABETIC PATIENTS WITH DIFFERENT DURATION F THE DISEASE
by: G. A. Batrak, et al.
Published: (2015-09-01)

Lipid-lowering effectiveness of a Russian generic of atorvastatin in patients with various hyperlipidaemia phenotypes
by: P. P. Malyshev, et al.
Published: (2009-12-01)

Dose-dependent effects of atorvastatin in the hospitalisation period of myocardial infarction
by: O. L. Barbarash, et al.
Published: (2013-06-01)

Triglyceride-glucose index for predicting repeat revascularization and in-stent restenosis in patients with chronic coronary syndrome undergoing percutaneous coronary intervention
by: Xuantong Guo, et al.
Published: (2023-03-01)

Possibilities of atorvastatin loading dose using for the prevention of perioperative myocardial damage in patients with stable coronary artery disease
by: A. S. Ragozina, et al.
Published: (2019-11-01)

The Effects of Atorvastatin on Cardiopulmonary Bypass Induced Inflammatory Response of Early Period and Intensive Care Unit Length of Stay After Coronary Artery Bypass Surgery
by: Coşkun Araz, et al.
Published: (2011-04-01)

ACUTE ATORVASTATIN RECAPTURE THERAPY IN CORONARY ARTERY BYPASS GRAFTING
by: A. V. Panov, et al.
Published: (2017-07-01)

Aggressive statin therapy in acute coronary syndrome: therapeutic potential of atorvastatin in the daily dose of 80 mg
by: A. N. Britov
Published: (2009-12-01)

Combined lipid lowering therapy, including ezetimibe, in the post-infarction period
by: V. E. Oleynikov, et al.
Published: (2024-05-01)

RNA Sequencing Reveals Beneficial Effects of Atorvastatin on Endothelial Cells in Acute Kawasaki Disease
by: Chisato Shimizu, et al.
Published: (2022-07-01)

Variations in Coronary Revascularization Practices and Their Effect on Long‐Term Outcomes
by: Rodolfo V. Rocha, et al.
Published: (2022-03-01)

Randomized study FARVATER: Part II. Atorvastatin effects on endothelial function, vascular wall distensibility and stiffness
by: A. V. Susekov, et al.
Published: (2007-06-01)